Evolution of the Average Target: Lexicon Pharmaceuticals, Inc.

Evolution of the Average Target - Lexicon Pharmaceuticals, Inc.

Evolution of the Target Price: Lexicon Pharmaceuticals, Inc.

Evolution of the Target Price - Lexicon Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Lexicon Pharmaceuticals, Inc.

f32c1db4de15.C_YTcI_1IOP_Sqooh0EJ-gpGnxmPkfdCHgwFBVQ3dyk.Yc5rNumcaLG0BcVFsid9mWwisij2xMItWjt1UCdQMFpDmHYz68BF07kM4w~fa82062a3e9562e261e0afc53a5321ef
09-28 Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating MT
09-28 Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target MT
11-06 Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025 CI
05/03/25 Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2 MT
22/11/24 HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating MT
17/06/24 HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target MT
30/04/24 Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target MT
31/05/23 Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating MT
07/03/23 Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target MT
12/08/22 Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target MT
01/07/22 Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating MT
11/10/21 Lexicon Pharmaceuticals : Wedbush Suspended Coverage on Lexicon Pharmaceuticals MT
30/08/21 Lexicon Pharmaceuticals : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating MT
11/05/21 Lexicon Pharmaceuticals : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept MT
29/01/21 Lexicon Pharmaceuticals : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7 MT
29/01/21 Lexicon Pharmaceuticals : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2 MT
08/12/20 Lexicon Pharmaceuticals : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10 MT
18/11/20 Lexicon Pharmaceuticals : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold MT
03/11/20 Lexicon Pharmaceuticals : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+153.65%
+38.52%
+18.89%
+8.54%
+13.54%
+21.07%
+30.77%
+68.83%
+19.8%
+59.35%
Average +43.30%
Weighted average by Cap. +28.79%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.780USD
Average target price
4.515USD
Spread / Average Target
+153.65%
High Price Target
8.000USD
Spread / Highest target
+349.44%
Low Price Target
1.690USD
Spread / Lowest Target
-5.06%

Analyst Consensus Detail

Analyst consensus - Lexicon Pharmaceuticals, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Lexicon Pharmaceuticals, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Lexicon Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. LXRX Stock
  4. Consensus Lexicon Pharmaceuticals, Inc.